Protocol Engineer

Cardano and Injective unlock first Live IBC link, bringing ADA and INJ across two ecosystems. Key Takeaways: * Cardano and Injective have enabled its first live IBC connection on testnet. * The integration allows ADA and INJ to seamlessly navigate the two different ecosystems. * The launch is a significant step towards bigger interoperability efforts within Cardano. User Score After launching the first testnet Inter-Blockchain Communication (IBC) with Injective, Cardano has made a significant stride toward cross-chain interoperability. The milestone establishes direct communication between the two blockchain ecosystems and opens new possibilities of using both ADA and INJ. Cardano and Injective Activate Live IBC Testnet Injective announced that it has become the first blockchain to establish a live onchain rail to Cardano via IBC on testnet. The integration will make ADA accessible in the Injective ecosystem, and INJ will be available on Cardano's side once the testnet function is used properly. JUST IN |: Cardano is now officially connected to Injective, the first blockchain to have a live onchain rail to Cardano via testnet.$ADA is coming to Injective. $INJ is coming to @Cardano. Both will be available across the two ecosystems. pic.twitter.com/ECnexrfx8c It is running in testnet to help developers test cross-chain transfers and interactions between applications prior to any full-scale deployment. IBC addresses the issue of intermediaries in traditional token bridges by allowing blockchain networks to interact at the protocol level. Expanding Cross-Chain Utility About the new connection that's more than a transfer of assets. It lays technical foundations for decentralized applications to communicate with one another and interact between blocks over both networks. A New Path for ADA and INJ Now, developers are able to get started experimenting with cross-chain applications, blending Cardano's ecosystem with Injective's decentralized finance infrastructure. Built on top of the Cosmos SDK, Injective already natively has IBC support. Cardano's Extended UTXO architecture was different from the account-based design of other Cosmos chains and therefore required some engineering work to integrate with Cardano. Both ecosystems can benefit from new opportunities for liquidity, decentralized finance (DeFi) and future application development, thanks to this working interoperability layer. Testnet First, Mainnet Later While being a big technical accomplishment, the integration is not production-ready yet. That means ADA and INJ holders will not immediately gain production-ready cross-chain functionality. Developers are expected to use the testing period to evaluate network stability, compatibility, and security before any mainnet deployment is considered. No launch date for a mainnet release has been announced by either project. Cardano Pushes Its Interoperability Strategy The latest milestone reiterates Cardano's larger journey to go over and beyond the native ecosystem. It has taken 2 years to develop infrastructure that will connect Cardano to a greater part of the wider interchain ecosystem powered by IBC work. The partnership enriches Injective's access to one of the biggest proof-of-stake blockchain communities. It satisfies a significant emerging need for Cardano to become more interconnected with external blockchain networks. The live IBC connection could pave the way for a wider appetite towards asset transfers across different chains, decentralized applications and liquidity sharing between Cardano, Injective and further IBC supported blockchains when the technology moves to the mainnet.

Why is Injective (INJ) up 6.50% today, August 12? A modest rebound meets a mixed daily structure. AI Market Summary Injective (INJ) gained 6.50% in 24 hours, outperforming a flat-to-slightly lower broader crypto market, suggesting token-specific positioning rather than macro beta. The move is framed as a technical rebound with active turnover, but with no confirmed same-day fundamental catalyst. Structure remains mixed: short-term averages were reclaimed while medium-term trend measures and nearby resistance remain unresolved, keeping follow-through sensitivity elevated. Impact level Affected assets INJ/USDT +4.04% AI Insight · INJ/USDT AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly. Injective (INJ) is up 6.50% as a modest rebound tests a mixed daily structure, with $4.74 acting as the key confirmation level. 3 key takeaways: INJ's 6.50% gain is a technical rebound. 1. INJ outperformed a flat broader market: the token gained 6.50% in 24 hours to $4.61, pointing to token-specific positioning rather than a market-wide rally. 2. No confirmed same-day catalyst has emerged: available evidence supports a technical and positioning-led rebound rather than a fresh protocol development. 3. The recovery remains incomplete: INJ has defended nearby support, but it still trades below key medium-term reclaim levels needed to strengthen the trend. INJ rises 6.50% as a modest rebound meets a mixed daily structure. Injective (INJ) rose 6.50% over the past 24 hours to $4.61 as of 02:48 UTC on August 12, lifting its market capitalization to about $461.17 million. The move came while total cryptocurrency market capitalization stood near $2.272 trillion, down 0.04% over the same period. INJ recorded roughly $69.10 million in 24-hour trading volume, equal to a 15.0% turnover rate against market capitalization. That activity shows active participation around the rebound, though it does not establish a fresh protocol-specific catalyst. The current advance reads as a modest recovery within a still-mixed daily technical structure. What is Injective in 2026? Injective is a blockchain network built for decentralized finance applications, with infrastructure designed for trading, derivatives, prediction markets, lending, and other on-chain financial products. Its architecture focuses on application-specific financial primitives and cross-chain connectivity. INJ is the network's native token. It supports functions across the ecosystem, including network security, governance, transaction-related activity, and participation in protocol mechanisms. Token performance can be influenced by broader crypto liquidity, network adoption, ecosystem announcements, and supply concentration. Why is Injective (INJ) up 6.50% today, August 12, 2026? 1. Technical rebound holds above $4.54. INJ held above the nearby $4.54 support area and rose to $4.61 within its recent $4.29 to $5.47 range. About $69.10 million in 24-hour volume, equal to a 15.0% turnover rate against market capitalization, shows active participation in the bounce. 2. No confirmed same-day protocol catalyst. No Injective-specific announcement or independently confirmed event was identified on August 12 to explain the move. The gain therefore appears more consistent with technical positioning than a confirmed fundamental repricing, leaving $4.74 as the first key test. 3. Cross-Chain context and relative strength. Cardano-Injective interoperability through the Inter-Blockchain Communication framework was reported during the prior week, adding context to the ecosystem narrative but not a confirmed explanation for this rally. INJ also outperformed while the total crypto market was marginally lower, which may reflect short-term token-specific demand. Technical outlook for INJ in August 2026. INJ has improved from its recent lows, though the daily chart has yet to confirm a broader trend reversal. Price action near $4.61 places the token above its shortest moving-average reference points while leaving several higher resistance and trend measures unresolved. Moving Average Structure: INJ trades above the 7-day simple moving average at $4.53 and the 7-day exponential moving average at $4.56. The 30-day simple moving average sits higher at $4.89, while the 30-day exponential moving average stands at $4.79. This setup shows near-term recovery inside a weaker medium-term structure. The 200-day simple and exponential references sit near $4.12 and $4.50. RSI Momentum: RSI(7) is 50.57, while RSI(14) and RSI(21) are 46.83 and 47.09. These readings place momentum near neutral, with short-term buying improving and no clear upside momentum expansion yet. MACD Signal: The MACD reading is negative at -0.12892, below its signal line at -0.08670, with a histogram of -0.04222. This points to lingering downside momentum on the daily structure even as spot price attempts a recovery. Support and Resistance Levels: Initial support sits at $4.54, followed by $4.29. Initial resistance stands near $4.74, with further reclaim levels at $4.88 and $5.02. Breakout Confirmation and Invalidation: A daily close above $4.74 with sustained volume would improve the short-term recovery case. A move back below $4.54 would place the lower range boundary in focus, while a break below $4.29 would invalidate the immediate rebound thesis. The technical picture supports caution around the current rally. INJ has reclaimed short-term averages and defended a nearby support zone, yet it remains below key 30-day trend references. The clearest data-led conclusion is that INJ's 6.50% gain represents a rebound attempt, with $4.74 serving as the first meaningful confirmation level. Conclusion: INJ's 6.50% rebound faces a $4.74 confirmation test. Injective's 6.50% rise to $4.61 has lifted the token above near-term support and short-term moving averages, supported by $69.10 million in 24-hour volume. Yet no confirmed same-day catalyst has emerged, and the daily technical picture remains mixed. Bull case: A completed daily close above $4.74 with sustained volume would strengthen the recovery signal and bring $4.88, then $5.02, into focus. That outcome would show buyers extending the move beyond the first overhead decision zone. Base case: INJ holds $4.54 while repeatedly testing $4.74. This would keep the token inside its established range and frame the current move as a tradable rebound rather than a confirmed broader reversal. Bear case: A completed daily close below $4.54 would shift attention to $4.29. A break below that lower range boundary would invalidate the immediate rebound thesis, while concentrated whale ownership could amplify price and liquidity swings. The next signal sits at $4.74. Holding above that level could open a test of $4.88 and $5.02, while rejection would keep INJ inside its established range. With 83.05% of supply concentrated among whale addresses, volatility and liquidity conditions remain central risks as the rebound develops.

INJ price stays quiet as Injective pushes major interoperability upgrade. Story Highlights * Injective activated IIP-677 after receiving 72% approval from governance voters. * IIP-678 remains under vote, with Abstain currently leading from 'Yes' votes. * Token Terminal reports approximately $3 million in protocol revenue over the past year. The INJ price has spent much of 2026 trapped between the $3 and $5 range, leading some to assume ecosystem development has slowed and it is the cause of muted price action. The governance record tells a different story. Injective has activated its IIP-677 interoperability mainnet upgrade (v1.20.3) while another core proposal, IIP-678, is already moving through the voting process. The latest upgrade follows earlier architectural expansions, including the Vulcan (IIP-650) upgrade and MultiVM rollouts, signaling that protocol development continues despite muted price action. Interoperability upgrade moves network forward. The approved IIP-677 proposal passed with 72% "Yes" votes after a four-day voting period. It commits the network to version v1.20.3, introducing targeted improvements aimed at strengthening Loading profile preview network operations, protocol reliability, market infrastructure, and cross-chain interoperability. The upgrade also seeks to integrate transfers from additional blockchains, enabling smoother asset movement into the Injective ecosystem while improving operational efficiency and network security. Earlier Vulcan enhancements had already introduced native canonical USDC settlement, reduced transaction fees, expanded real-world asset (RWA) markets, and deployed a next-generation oracle engine alongside refined exchange, insurance, and oracle modules supporting faster buyback and burn cycles. Another governance vote remains open. Development hasn't paused there. IIP-678 remains under active voting until July 31, focusing on recovering an expired IBC light client connected to the QUAD Core chain. The proposal replaces the expired client with an active substitute while maintaining the existing connection and channel. According to the current vote tally, Abstain holds 52.81%, while Yes accounts for 47.18%. Whether that balance changes before voting closes remains to be seen. Revenue keeps rising despite flat price. The INJ price may appear less interesting to many, but protocol activity paints another picture. Injective's governance page has progressed from approximately IIP-615 earlier this year to IIP-678, reflecting more than 60 governance proposals during 2026. Meanwhile, Token Terminal reports approximately $3.0 million in protocol revenue over the past 365 days, generated through its dual-chain architecture. Revenue combines burn auctions on Injective Cosmos and EIP-1559 base fee burns on Injective EVM, highlighting continued protocol activity even while the INJ price remains range-bound. Loading article prices